By: Abdul Haseeb, Ph.D. Drugging the Undruggable Tremendous progress in genomics, transcriptomics and proteomics has led to the discovery of thousands of new drivers of disease, but drug discovery...
Read More
MALVERN, Pa., SEP 1, 2022 – LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glues, and neurodegeneration diagnostics, is pleased to announce that Lifesensors has published…
LifeSensors is Attending ASCB | EMBO Cell Bio 2022 MALVERN, PA., AUG 30, 2022 -- LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTACs, molecular glues, and neurodegeneration...
Read More
LifeSensors Invited to Speak at the Industry’s Preeminent 20th Annual Discovery on Target Conference
LifeSensors Invited to Speak at the Industry’s Preeminent 20th Annual Discovery on Target Conference MALVERN, Pa., AUG 30, 2022 -- LifeSensors Inc., a Biotech and Drug Discovery Company focused on...
Read More
LifeSensors Attending the 5th Annual Targeted Protein Degradation Summit MALVERN, PA., AUG 30, 2022 -- LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, Molecular Glues, and neurodegeneration...
Read More
By: Rebekah Varghese, Derrick Padykula, & Jacob Huang All the FDA-approved drugs combined interact with only 2% of the proteins found in human cells, according to Dr. Brent Stockwell, a…
By: Rebekah Varghese and Derrick Padykula Parkinson’s Disease (PD) is the second most common neurodegenerative disease, affecting 1-2% of the population. Now, when you consider the world’s population to be…
The Ubiquitin-Proteasome System: An Overview The Ubiquitin-Proteasome system (UPS) is a highly complex, temporally controlled and conserved pathway that plays a major role in a myriad on cellular functions….